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Introduction: Small cell lung cancer (SCLC) is an aggressive 
malignancy that although initially sensitive to chemo- and radiation 
therapy, inevitably relapses resulting in poor survival. Increasing 
evidence suggests that immune responses against SCLC cells make 
immunotherapy a viable therapeutic approach. Furthermore, preclin-
ical data have shown that certain chemotherapeutic regimens may 
augment the immunotherapeutic response in SCLC. This review dis-
cusses current evidence supporting immunotherapy for SCLC, prog-
ress made, and ongoing clinical trials.
Methods: We searched PubMed and abstracts presented at recent 
oncology congresses for publications on the clinical benefit of immu-
notherapy/checkpoint blockade for treatment of SCLC.
Results: Preliminary data from ongoing clinical trials in SCLC have 
shown that some antiangiogenic agents, vaccines, and immunomodu-
lators, including interferon-α and immune checkpoint blockers (i.e., 
anticytotoxic T-lymphocyte-associated antigen-4 [CTLA-4] antibod-
ies) may be efficacious as single agents and in combination with 
standard-of-care regimens. Notably, in a phase II trial, ipilimumab—
a fully human anti-CTLA-4 monoclonal antibody recently approved 
for treatment of unresectable or metastatic melanoma—demonstrated 
encouraging results when used as part of a chemoimmunotherapeu-
tic regimen in patients with SCLC. Ipilimumab is undergoing further 
investigation in this population.
Conclusions: Treatment options for SCLC are limited and progno-
sis poor, emphasizing the need for novel treatments. Although cur-
rent strategies successfully induce a response, the response is not 
durable. Evidence of an immune response in SCLC and a better 
understanding of the immunosuppressive tumor environment sup-
port the combinatorial use of immunomodulators, such as ipilim-
umab, with traditional chemotherapy regimens to improve patient 
outcomes and potentially sustain the effect from chemotherapeutic 
induction.
Key Words: Cytotoxic T-lymphocyte-associated antigen-4 blockade, 
Immunomodulators, Ipilimumab, Small cell lung cancer.
(J Thorac Oncol. 2013;8: 587–598)
Small cell lung cancer (SCLC) is a rapidly growing malig-nancy with a poor prognosis. Extensive research over the 
past three decades has greatly expanded the anticancer arma-
mentarium for certain types of non–small cell lung cancer 
(NSCLC), but research in SCLC has failed to identify treat-
ments that extend clinical benefit beyond standard-of-care 
treatment. Thoracic radiotherapy in combination with che-
motherapy is recommended for the treatment of patients with 
limited-disease SCLC (LD-SCLC). Similarly, prophylactic 
cranial irradiation (PCI) is recommended for patients with 
either LD-SCLC or extensive-disease SCLC (ED-SCLC), who 
attain a complete or partial response after initial treatment.1 
Notably, both thoracic radiotherapy and PCI have resulted in 
increased survival in LD-SCLC and ED-SCLC when com-
pared with chemotherapy alone. Recent studies demonstrate 
that immune responses may occur against tumor cells of the 
lung, including SCLC, suggesting that immunotherapy may be 
a novel approach for the treatment of SCLC. Immunotherapy 
aims to enhance the immune system’s ability to recognize and 
specifically eliminate cancer cells while minimally impacting 
healthy lung tissue. This article provides a detailed overview 
of immunotherapeutic agents under investigation in SCLC and 
the challenges of immunotherapy in this tumor type.
BACKGROUND
Lung cancer is the most common cancer worldwide. 
In 2008, there were an estimated 1.61 million new cases of 
lung cancer, representing 13% of all new cancers in the world.2 
Lung cancer was also the most common cause of death from 
cancer in 2008, accounting for 1.38 million deaths (18% of the 
total).2 SCLC comprises 15% to 20% of lung cancer cases,3 
with approximately 30,000 new cases of SCLC expected to be 
diagnosed in the United States in 2012.4 Untreated SCLC has 
an aggressive clinical course characterized by rapid growth and 
a tendency to metastasize early.5 SCLC is often initially highly 
sensitive to chemotherapy and radiation therapy; however, the 
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majority of patients will experience relapses, and long-term 
survival is rare.5
SCLC: Limited Versus Extensive Disease
On the basis of a staging system developed and revised 
by the Veteran’s Administration Lung Cancer Study group 
in the United States, SCLC has traditionally been classified 
into two stages according to the extent of disease—LD-SCLC 
and ED-SCLC.6 By definition, LD-SCLC, which represents 
approximately 30% of new SCLC cases is confined to one 
hemithorax with regional lymph node metastasis and can 
be encompassed within a single radiation port,7 whereas 
ED-SCLC (describes the remaining 70% of new cases) 
extends beyond the boundaries of a single radiation port, 
where cancer has spread beyond the ipsilateral hemithorax, 
or metastasized to distant locations of the body.7 A new lung 
cancer tumor, node, metastasis staging system was developed 
by the International Association of the Study of Lung Cancer 
and adopted by the American Joint Commission for Cancer. It 
is suggested that clinical research studies use the tumor, node, 
metastasis system to permit more accurate assessments of 
prognosis and specific therapy for patients.1
CURRENT TREATMENT OPTIONS FOR SCLC
First-Line Treatment with Chemotherapy
When left untreated, the life expectancy for patients 
with SCLC is approximately 4 to 6 months.8,9 Treatment for 
LD-SCLC is used with curative intent through a combined 
therapeutic approach typically involving thoracic radiother-
apy, chemotherapy, and rarely, surgery.5 Unfortunately, the 
majority of patients diagnosed with SCLC already have exten-
sive-stage disease at presentation. Therapy for these patients is 
limited to platinum-doublet chemotherapy.5 Meta-analyses of 
several trials have shown that platinum-containing regimens 
provide a modest, but statistically significant increase in sur-
vival over non–platinum-containing therapies.10,11 First devel-
oped in the early 1980s, four to six cycles of platinum and 
etoposide (PE) have remained standard-of-care first-line che-
motherapy for both LD- and ED-SCLC.9 In consideration of 
at-risk populations, such as the elderly, etoposide plus cispla-
tin is a recommended standard of care, which is in alignment 
with treatment recommendations for the general treatment of 
SCLC based on data from phase III trials.1 Notably, however, 
a regimen of carboplatin plus etoposide can be an alternative 
for patients with SCLC when considering the risk–benefit 
balance.12 Currently, etoposide and platinum plus concurrent 
thoracic radiotherapy is a recommended standard treatment 
for patients with LD-SCLC.1 Importantly, meta-analyses of 
more than 2000 patients with LD-SCLC demonstrated that 
thoracic radiotherapy resulted in a 5% to 7% improvement in 
2-year survival when compared with chemotherapy alone.13,14 
Likewise, a systematic review evaluating early versus late 
time of thoracic radiation therapy in LD-SCLC demonstrated 
that there was a significantly increased 2-year survival for 
early radiation therapy compared with late radiation therapy—
overall survival (OS) risk ratios for all studies were 1.17 at 2 
years (95% confidence interval [CI], 1.02–1.35; p = 0.03).15 
Reviews of trial data and other meta-analyses, such as that by 
Socinski and Bogart,16 support the finding that early and con-
current thoracic radiotherapy with chemotherapy is optimal for 
the treatment of patients with LD-SCLC. Additionally, PCI is 
recommended for patients with either LD-SCLC or ED-SCLC 
and good performance status (PS), who attain at least a par-
tial response to initial therapy.17,18 PCI has demonstrated an 
increase in 1-year survival in patients with ED-SCLC when 
compared with controls (27.1% versus 13.3%, respectively).17 
Furthermore, a meta-analysis of all randomized PCI tri-
als using individual patient data reported a 5.4% increase in 
3-year survival in patients treated with PCI compared with 
the control group (20.7% versus 15.3%, respectively).19 This 
observation was consistent between patients with LD-SCLC 
and ED-SCLC, despite the small number of patients in the 
ED-SCLC group. More recently, a retrospective analysis of 
patients with LD-SCLC confirmed this observation with the 
finding that PCI increased survival at 2, 5, and 10 years com-
pared with those who did not receive PCI.20
In an attempt to expound on the combination of plati-
num and etoposide for the first-line treatment of ED-SCLC, a 
phase II trial (Cancer and Leukemia group B 30103) assessed 
the efficacy and tolerability of carboplatin and etoposide with 
or without the Bcl-2 antisense oligonucleotide oblimersen in 
56 patients. Carboplatin and etoposide with oblimersen was 
associated with slightly more grade 3/4 hematologic toxic-
ity than carboplatin and etoposide alone (88% versus 60%, 
respectively; p = 0.05), and response rates were similar 
between both arms (61% versus 60%, respectively). Hazard 
ratios (HRs) for failure-free survival (1.79; p = 0.07) and OS 
(2.13; p = 0.02) suggested worse outcome for patients receiv-
ing carboplatin and etoposide with oblimersen. Results from 
this study show that addition of oblimersen to standard first-
line treatment for SCLC did not improve clinical outcomes.21
As stated above, many SCLC tumors are initially respon-
sive to treatment, with an expected 70% to 90% response rate 
among patients with LD-SCLC treated with PE plus thoracic 
radiotherapy, and an approximate 50% to 70% response rate 
in patients with ED-SCLC treated with PE alone.1 These ini-
tial responses, however, do not correspond to high survival 
rates. Median survival for patients with LD-SCLC receiv-
ing standard therapy is 18 to 30 months,22 whereas patients 
with ED-SCLC experience median survival in the range of 10 
to 12 months.10 These data translate to poor 5-year survival 
rates for SCLC, reported to be as low as 10% to 15%22 and 
as high as 20% to 25%7 for LD-SCLC and only 1% to 2% for 
ED-SCLC.10
First-Line Treatment with 
Antiangiogenic Agents
Cancer cell growth is highly dependent on angiogene-
sis, a process mediated predominantly by vascular endothelial 
growth factor (VEgF) and its receptors. Because approxi-
mately 80% of SCLC tumors overexpress VEgF, antiangio-
genic therapy has been pursued as a novel approach to treat 
this malignancy.
Several phase II studies have investigated the effects of 
adding bevacizumab to chemotherapy regimens for the first-line 
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treatment of ED-SCLC.23–26 In a phase II study, it was found 
that bevacizumab given in combination with chemoradiation 
increased the risk of tracheoesophageal fistulas in patients 
with LD-SCLC,27 and therefore, future clinical development 
of bevacizumab in SCLC was restricted to patients with 
extensive disease. In the Eastern Cooperative Oncology group 
(ECOg) phase II, single-arm study E3501,23 bevacizumab 
given in combination with cisplatin and etoposide, followed 
by maintenance bevacizumab monotherapy until death or 
disease progression, achieved improved progression-free 
survival (PFS) and OS in patients with previously untreated 
ED-SCLC, compared with historical controls in whom a 
chemotherapy regimen was given without bevacizumab.28–30 
The overall response rate in study E3501 was 63.5%, median 
PFS was 4.7 months (95% CI, 4.3–5.5 months), and median 
OS was 10.9 months (95% CI, 7.9–12.2 months).23
Another single-arm phase II study in which patients 
with previously untreated ED-SCLC were administered beva-
cizumab, carboplatin, and irinotecan produced a promising 
objective response rate of 84% (95% CI, 71%–93%), median 
time to progression of 9.13 months (95% CI, 7.36–9.46 
months), and median OS of 12.1 months (95% CI, 9.6–13.5 
months).24 These encouraging findings were recently reca-
pitulated in a single-arm phase II study, in which patients 
with previously untreated ED-SCLC who received bevaci-
zumab, cisplatin, and irinotecan showed an overall response 
rate of 75%, median PFS of 7.0 months (95% CI, 6.4–8.4 
months), and a median OS of 11.6 months (95% CI, 10.5–15.1 
months).26 The randomized, double-blind, placebo-controlled 
phase II SALUTE study, which directly compared the efficacy 
of adding bevacizumab to a regimen of PE in 102 patients with 
ED-SCLC showed that addition of bevacizumab to a PE regi-
men prolonged median PFS (5.5 months in the bevacizumab 
arm versus 4.4 months in the placebo arm; HR = 0.53; 95% 
CI, 0.32–0.86)—the primary endpoint of this trial.25 However, 
there was no significant benefit of bevacizumab on median OS 
(9.4 months in the bevacizumab arm versus 10.9 months in 
the placebo arm; HR = 1.16; 95% CI, 0.66–2.04).25 The safety 
profile for bevacizumab in this study was consistent with that 
seen with its use in the treatment of other solid tumors.
The efficacy of thalidomide, a drug with reported anti-
angiogenic activity, was investigated in a single-arm, phase 
II trial of 25 chemotherapy-naive patients with SCLC.31 A 
regimen of carboplatin and etoposide given concurrently with 
thalidomide in these patients, followed by thalidomide main-
tenance for up to 2 years, resulted in a median PFS of 8.3 
months and a median OS of 10.1 months.31 These data led to a 
larger phase III trial, involving 724 patients with SCLC (51% 
LD-SCLC; 49% ED-SCLC), who were randomized to receive 
either placebo or thalidomide, in addition to a regimen of car-
boplatin plus etoposide.32 The median OS was 10.5 months 
in the placebo group and 10.1 months in the thalidomide 
group (HR = 1.09; 95% CI, 0.93–1.27; p = 0.28). The addi-
tion of thalidomide to a chemotherapy regimen of etoposide 
plus carboplatin did not significantly improve survival among 
patients with LD-SCLC (HR = 0.91; 95% CI, 0.73–1.15) and 
was associated with reduced survival among patients with 
ED-SCLC (HR = 1.36; 95% CI, 1.10–1.68).32
Similarly, matrix metalloproteinases (MMPs)—a family 
of enzymes that proteolytically degrade various components 
of the extracellular matrix—support the process of angiogen-
esis.33 The expression of MMPs has been found to be elevated 
in SCLC and this expression has also been identified as an 
independent negative predictor of survival.34 Preclinical stud-
ies in animal models of malignancy showed that MMP inhibi-
tors (MMPIs) could prevent the growth and regional spread 
of solid tumors.35,36 The utility of MMPIs in the first-line set-
ting have been investigated clinically. In a phase III trial of 
532 eligible patients previously treated with induction che-
motherapy (the majority of whom presented with LD-SCLC), 
266 patients received the MMPI—marimastat—whereas the 
remaining 266 received placebo. Results from the trial showed 
that the difference in median survival between patients treated 
with marimastat and placebo was not statistically significant 
(9.3 versus 9.7 months, respectively; p = 0.90).37 Likewise, 
there was no apparent difference in the median time to pro-
gression between patients treated with marimastat and placebo 
(4.3 versus 4.4 months, respectively; p = 0.81). Importantly, 
treatment with marimastat also had a negative impact on qual-
ity of life.
Second-Line Treatment
An estimated 80% of patients with LD-SCLC, and all 
patients with ED-SCLC experience disease progression or 
relapse in response to first-line platinum-based therapy.38 A 
patient’s response to first-line treatment and the duration of 
the subsequent progression-free period influences the likeli-
hood that a patient will respond to second-line chemother-
apy.39 Tumors that are refractory to first-line chemotherapy or 
relapse within 60 to 90 days are considered chemoresistant, 
whereas tumors whose response to first-line therapy exceeds 
60 to 90 days are considered to be chemosensitive.9
Patients in whom response to first-line therapy is 
maintained for longer than 180 days are likely to benefit 
from retreatment with platinum-based chemotherapy (i.e., 
reinduction therapy).9 Platinum reinduction therapy is not 
recommended in patients whose disease relapses between 90 
and 180 days after completing first-line treatment. Single-
agent topotecan is the only second-line therapy approved 
by the U.S. Food and Drug Administration for the treatment 
of relapsed SCLC for which reinduction with the first-line 
regimen is not considered appropriate.9 Approval was based on 
a randomized trial in which single-agent intravenous topotecan 
was shown to be at least as effective in terms of response 
rates and survival as the cyclophosphamide, doxorubicin, and 
vincristine (CAV) regimen in relapsed SCLC patients (n = 
211).40 Response rates were 24.3% and 18.3% for topotecan 
and CAV, respectively (p = 0.285), and median survival was 
similar between arms, with 25 weeks for topotecan and 24.7 
weeks for CAV (p = 0.795). Significant improvements with 
regard to side effects (notably dyspnea, anorexia, hoarseness, 
fatigue, and interference with daily activity) were observed 
in the topotecan group compared with those receiving CAV.40 
Oral topotecan in combination with best supportive care 
has demonstrated a survival advantage over best supportive 
care alone in patients with relapsed SCLC,41 and shown 
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comparable efficacy to the intravenous formulation.42 In a 
randomized phase II trial (Southwest Oncology group 0802) 
of intravenous topotecan with and without the VEgF Trap 
AVE0005 (aflibercept) in patients with platinum-treated 
ED-SCLC, the primary endpoint (3-month PFS) was met for 
the combination of aflibercept and topotecan versus topotecan 
alone (26% versus 9%, respectively; p = 0.01); OS, however, 
was similar in each arm (4.6 versus 3.9 months, respectively; 
p = 0.25).43 Side effects were mainly hematologic with 19% 
and 14% of patients experiencing a grade 4 event with the 
combination of aflibercept and topotecan versus topotecan 
alone, respectively.43
Irinotecan, paclitaxel, gemcitabine, vinorelbine, and 
docetaxel are all used as second-line alternatives to topote-
can.44 Additionally, agents such as amrubicin,45 picoplatin,46 
belotecan,47 and bendamustine48 are currently being evaluated 
as potential treatment options in phase II/III clinical studies in 
relapsed SCLC patients, though to date no substantial progress 
has been made over topotecan in improving OS in this setting.
Results from a randomized, phase III study compar-
ing amrubicin with topotecan in 637 patients with relapsed 
(chemosensitive or chemoresistant) SCLC showed a signifi-
cantly higher response rate with amrubicin than topotecan 
(31% versus 17%, respectively; odds ratio [OR] = 2.22; 95% 
CI, 1.47–3.36; p = 0.0002); however, the primary endpoint of 
median OS was similar in the two treatment groups (7.5 ver-
sus 7.8 months, respectively; HR = 0.88; 95% CI, 0.73–1.06; 
p = 0.17), as was median PFS (4.1 versus 4.0 months, respec-
tively; HR = 0.999; 95% CI, 0.84–1.19; p = 0.98).45 Subgroup 
analyses indicated improved OS with amrubicin compared 
with topotecan among patients with chemoresistant/refrac-
tory disease (6.2 versus 5.7 months, respectively; HR = 0.77; 
95% CI, 0.59–1.0; p = 0.047), but not in those with sensi-
tive relapse (9.2 versus 10 months, respectively; HR = 0.94; 
95% CI, 0.72–1.21; p = 0.62). Significantly lower incidences 
of neutropenia, thrombocytopenia, anemia, and a reduced 
requirement for transfusion favored amrubicin in this study.45
In the SPEAR study, picoplatin, a novel platinum com-
pound designed to overcome platinum resistance, was evalu-
ated for safety and efficacy compared with best supportive care 
in 401 patients with SCLC, refractory or progressive within 6 
months, after first-line platinum-based chemotherapy.46 The 
primary endpoint of this randomized phase III study was OS. 
Survival analysis of 321 events showed that this trial did not 
achieve statistical significance (p = 0.09), with an imbalanced 
use of poststudy chemotherapy as a factor that may have 
affected this result.46
Belotecan, a topoisomerase I inhibitor, demonstrated 
modest activity in the second-line treatment of sensitive relapse 
after irinotecan plus platinum therapy in a phase II study in 
Korea, with an overall response rate of 22% among 25 evalu-
able patients and median survival of 13.1 months (95% CI, 
10.4–15.8 months).47 In an ongoing multicenter phase II study, 
treatment with bendamustine, an alkylating agent, achieved a 
partial response in 7 of 19 evaluable patients receiving it as 
second- or third-line treatment for relapsed disease.48
Attempts to optimize chemotherapeutic intervention 
have been explored. However, dose-dense chemotherapy with 
growth factors49,50 or without growth factors,51 triplet chemo-
therapy,52,53 quadruple chemotherapy,54 and chemotherapy in 
which etoposide is replaced with another agent as part of the 
platinum doublet55–58 have not clearly demonstrated improve-
ments in patient survival in clinical trials. Attempts at non-
chemotherapeutic and targeted approaches within a clinical 
trial setting have largely been unsuccessful. Moreover, no 
trials of maintenance therapy have reported patient survival 
improvements or substantially lengthened responses to first-
line chemotherapy.7
Low response rates associated with topotecan in the sec-
ond-line treatment setting and the heterogeneity of SCLC—
characterized by mutations or aberrant expression of a key 
apoptotic inhibitor (Bcl-2)—have fostered the clinical devel-
opment of other small molecules for the treatment of relapsed 
SCLC. In a phase II study of navitoclax (ABT-263)—a potent 
and selective inhibitor of Bcl-2 and Bcl-x
L
—39 patients with 
relapsed SCLC received navitoclax 325 mg daily after an ini-
tial lead-in of 150 mg daily for 7 days.59 The most common 
side effect was thrombocytopenia. Median PFS and OS were 
1.5 and 3.2 months, respectively. In this trial, single-agent 
navitoclax demonstrated limited single-agent activity in recur-
rent SCLC. In another phase II trial of patients with relapsed 
SCLC, the Bcl-2 antagonist obatoclax mesylate was combined 
with topotecan.60 Intravenous obatoclax mesylate 14 mg/m2 
was administered on days 1 and 3 with intravenous topotecan 
1.25 mg/m2 on days 1 to 5 every 3 weeks. This study did not 
meet its primary endpoint of overall response and there were 
no partial or complete responses. Common grade 3/4 adverse 
events included thrombocytopenia, anemia, neutropenia, and 
ataxia.60
As in the first-line treatment of SCLC, the therapeutic 
potential of targeted agents has also been explored in the 
relapsed setting. For example, the efficacy of thalidomide 
was assessed in patients with ED-SCLC who had previously 
received chemotherapy in a small phase III study (n = 
119).61 Patients who responded to two initial cycles of 
chemotherapy with etoposide, cisplatin, cyclophosphamide 
and 4′-epidoxorubicin (PCDE) were randomized to receive 
four further PCDE cycles in combination with placebo or 
thalidomide. Overall, thalidomide was not associated with a 
significant improvement in survival, although there was some 
evidence of slower progression and longer survival in patients 
with a PS of 1 to 2.61Another antiangiogenic agent, cediranib, 
was found to have no clinical activity in a phase II trial of 
patients with relapsed/recurrent SCLC as monotherapy.62 Just 
as marimastat was assessed in the first-line setting, another 
MMPI, BAY12-9566, was assessed in the second-line setting 
as adjuvant therapy for patients with SCLC. Two independent, 
multicenter phase III trials of patients with unresectable SCLC 
showed that there was no significant difference in survival 
between patients receiving BAY12-9566 and placebo.63 
Collectively, results from these trials show that SCLC is a 
malignancy in which little clinical progress has been made 
with regard to novel classes of agents. As such, there is 
clearly a need for innovative therapies to improve the dismal 
outcomes for this disease.
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Tumor Immunology and the Antitumor 
Immune Response to SCLC
The immune system has two interconnected components: 
the innate system and the adaptive (acquired) system.64 The 
innate immune system provides rapid, but nonspecific protection 
against foreign or dangerous substances with certain properties 
and does not display memory to specific antigens. However, the 
adaptive immune system responds to specific antigens, with 
repeat exposure leading to a more robust response in a phenom-
enon known as immunologic memory. The innate and adaptive 
branches of the immune system interact with each other to rec-
ognize and defend the host against harmful substances while 
maintaining tolerance to “self.”
Research to date has demonstrated that some tumors may 
have properties that trigger responses from both the innate and 
adaptive branches of the immune system.65 Moreover, some 
evidence suggests that in certain instances the immune system 
is capable of controlling or even eradicating tumor growth.65 
However, in other cases, cancer growth proceeds when tumor 
cells are able to “escape” host immune control. Multiple 
mechanisms have been proposed for this phenomenon,66,67 
including the induction of immune tolerance.68
A critical part of the adaptive immune system is the 
network of pathways that mediate antigen-specific activation 
of effector T cells (Teffs). Activated Teffs target tumor cells 
directly or mediate subsequent humoral antitumor responses. 
Activated T cells and antibodies specific to tumor-associated 
antigens have been isolated from patients with a variety of 
tumor types.69 After T-cell activation in response to a specific 
antigen, a subset of lymphocytes called regulatory T cells 
(Tregs) plays a major role in down-regulating the resulting 
immune response and establishing immune tolerance to the 
antigens, thereby allowing the body to suppress autoimmu-
nity. Ordinarily, suppression of autoimmunity is desirable; 
however, in the setting of cancer it may contribute to poor 
outcome. Tregs have been shown to down-regulate antigen-
specific immune responses to tumor cells in various cancer 
types, including SCLC.70,71 Studies have shown that Treg cell 
numbers are higher in patients with cancer and that the num-
ber of Tregs correlates with prognosis.72–74 Treg cells that pre-
vent autoimmune diseases by suppression of self-reactive T 
cells may also suppress the immune response against cancer.
Immunotherapy is designed to elicit an anticancer 
response by modulating the patient’s immune response to the 
tumor, specifically by enhancing host immune surveillance 
and/or decreasing tolerance to tumor cells. Several lines of 
evidence support the existence of an ongoing, although sup-
pressed, immune response against SCLC tumors. One example 
may be found in the occurrence of Lambert–Eaton myasthenic 
syndrome (LEMS), a paraneoplastic syndrome observed in a 
small percentage of SCLC patients. Patients with this immune-
mediated syndrome tend to have a more favorable prognosis 
than patients without LEMS, and it has been hypothesized that 
the immune effects responsible for the neuromuscular damage 
associated with LEMS are also responsible for suppressing 
SCLC tumor growth.75
Other data, although limited in scope, are suggestive 
of an ongoing antitumor immune response, which is being 
actively suppressed. An analysis of T cells in peripheral blood 
samples from 35 SCLC patients revealed higher counts of 
Teffs in LD-SCLC patients than in ED-SCLC patients.75 In 
addition, long-term survivors of SCLC were found to main-
tain a high ratio of Teff-to-Treg cells, whereas patients with 
recurrent disease exhibited a low ratio of Teffs-to-Tregs. These 
results suggest that a Teff-to-Treg balance may be a potential 
biomarker that distinguishes ED-SCLC from LD-SCLC and is 
predictive of recurrence. The results also support the hypothe-
sis that immunotherapy, by shifting the T-cell balance in favor 
of Teffs and/or abrogating the Treg population, may promote a 
more effective antitumor immune response to SCLC.75
Additionally, there is mounting evidence that the 
immune system may contribute to the control of cancer in con-
cert with conventional chemotherapy or radiotherapy. Tumor 
cell death that follows radiotherapy and some chemothera-
peutic agents can induce immunostimulatory effects, possi-
bly by encouraging tumor antigen-specific immune responses 
or by altering the immunologic properties of any remaining 
tumor cells. This anticancer immune response then helps to 
eliminate residual cancer cells that survived chemotherapy or 
radiotherapy. The immune response may also maintain micro-
metastases in a stage of dormancy.76 It has been hypothesized 
that certain chemotherapeutic regimens may enhance immu-
nologic responses against the tumor through a direct altera-
tion of immune effectors or immune regulatory mechanisms. 
This immune enhancement phenomenon may also be a con-
sequence of immune effector cell proliferation in response to 
chemotherapy- or radiation-induced lymphopenia.76
NEW APPROACHES TO SCLC
The biology of SCLC is complex and has not been fully 
elucidated, which contributes to the challenge of developing 
targeted therapies that demonstrate clinical benefit.77 Among 
the approaches that have been recently evaluated in phase II/III 
studies are molecular targeted therapies—notably, approaches 
that seek to modulate the immune response to SCLC.
Vaccines
Tumor vaccines are designed to present tumor antigens 
to the adaptive immune system, thereby promoting a more 
effective response against the tumor. gD3 is a cell membrane 
ganglioside that has been shown to be overexpressed 
in approximately 60% of SCLC tumors,78 and has been 
investigated as a potential vaccine target for this form of 
cancer. Bec2, an anti-idiotypic monoclonal antibody that 
induces antiganglioside gD3 antibodies, was explored in a 
small phase I/II trial in which LD-SCLC patients achieving 
a partial or complete response to induction therapy were 
vaccinated with Bec2/bacille Calmette–guerin. Improved 
survival was noted among those patients who developed 
anti-gD3 antibodies compared with historical controls.79 
However, results from a subsequent randomized, phase III trial 
in 515 LD-SCLC patients who had responded to induction 
chemoradiotherapy were not encouraging. The study findings 
indicated that maintenance therapy with the vaccine provided 
no survival benefit and failed to improve quality of life.80 In 
fact, only one third of evaluable patients in the vaccine arm 
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of the study developed a humoral response. The numerical 
improvement in survival noted for this subgroup compared 
with nonresponders (19.2 versus 13.9 months, respectively; 
p = 0.085) was not statistically significant, particularly after 
adjusting for the use of PCI between the two subgroups.80
Immunomodulators
Immunomodulators, whose mechanisms of action are 
independent of specific tumor antigen recognition, are attrac-
tive candidates for SCLC therapy based on the rationale dis-
cussed above. The role of interferon (IFN)-α as a treatment 
option for patients with SCLC remains uncertain because of 
the lack of large, well-designed, randomized phase III trials 
in this setting. Blockade of the immune checkpoint protein, 
cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), is 
proving to be a more promising strategy, but requires further 
validation in larger studies.
Interferon -α
IFN-α is a cytokine that not only stimulates immune 
cells, but also promotes antigen presentation on tumor cells, 
in theory allowing cancer cells to be more easily recognized 
by the immune system. IFN-α was evaluated as maintenance 
therapy for SCLC in two important clinical trials more than a 
decade ago, both of which suggest that it may act synergisti-
cally with chemotherapeutic agents.81,82
The first of these studies enrolled 237 responders to 
induction chemoradiotherapy and found there was no difference 
in median survival between patients who were then random-
ized to receive maintenance therapy with natural IFN-α, main-
tenance chemotherapy (cyclophosphamide, adriamycin, and 
cisplatin), and a control group receiving no maintenance treat-
ment.83 Median survival in this phase III trial was 11 months 
in the two maintenance therapy groups and 10 months in the 
control group.83 However, there was an apparent significant dif-
ference in long-term survival for patients with LD-SCLC, in 
favor of IFN-α maintenance therapy (p = 0.04).81 Follow-up at 
5 years found that 10% of patients in the IFN-α group survived 
compared with only 2% in the cyclophosphamide, adriamycin, 
and cisplatin and control groups. All long-term survivors had 
good PS, and the majority had LD-SCLC and had achieved a 
complete response to induction therapy.81 These findings fail 
to lend support to a role for IFN-α in maintaining a clinically 
disease-free status achieved with induction treatment.
A second study investigated the feasibility of mainte-
nance therapy with IFN-α plus retinoic acid after a high-dose 
combination of chemotherapy and radiotherapy in patients 
with SCLC.82 Patients in this multicenter, phase II study who 
responded to chemotherapy and radiotherapy were randomly 
assigned to one of three maintenance therapy arms: IFN-α 
and retinoic acid, trophosphamide, or no maintenance treat-
ment (control). Median survival time among the randomized 
patients was 17.1 months in the IFN-α plus retinoic acid arm, 
12.4 months in the trophosphamide arm, and 13.5 months in 
the control arm, and did not differ significantly between groups. 
The 1-year survival rate was higher in the IFN-α plus reti-
noic acid arm (82%) than in the comparator arms (55–56%), 
and patients treated with IFN-α plus retinoic acid tended to 
survive longer after the onset of progressive disease, though 
these differences did not reach statistical significance.82
The lack of statistically significant outcomes reported 
in both studies with IFN-α maintenance therapy have led 
to its cessation of development as an SCLC treatment.81–83 
Moreover, a systematic review by Rossi et al.84 on pooled data 
from 3688 patients with SCLC confirmed the lack of sur-
vival benefit received from maintenance therapy with IFN-α. 
Collectively, these trial results do not suggest that immuno-
modulating agents complement chemotherapy/radiotherapy 
induction treatment in a manner that would improve long-term 
outcomes for patients with SCLC.
Immune Checkpoint Proteins
As part of the regulatory pathways that maintain a bal-
ance between appropriate recognition and destruction of patho-
gens or tumors and inappropriate overstimulation of immune 
responses, costimulatory and coinhibitory factors function 
to fine-tune the antigen-specific T-cell response after stimu-
lation of the T-cell receptor.85,86 T-cell receptor recognition of 
antigenic peptides in the context of major histocompatibility 
complex molecules on the surface of antigen-presenting cells 
(APCs) is the first step in the generation of a specific T-cell 
response. Full T-cell activation requires a second “costimu-
latory” signal—this second signal is generated when the 
costimulatory receptor on the surface of T cells, CD28, binds 
to B7 ligand subtypes CD80 and CD86 on the APC (Fig. 1). 
Costimulation through CD28, and other such molecules 
including CD134, and CD137, supplements the excitatory 
antigen stimulation signal that leads to T-cell activation and 
thereby helps to potentiate the immune response. Conversely, 
coinhibition through molecules like CTLA-4, programmed 
death-1 (PD-1), B7-H3, and B7x diminishes antigen-specific 
immune responses by limiting their magnitude and duration. 
For this reason, these coinhibitory molecules are collectively 
dubbed “immune checkpoint proteins.”
CTLA-4 is a well-studied immune checkpoint protein 
that is expressed on activated T cells and functions to down-
regulate T-cell activity.87 CTLA-4 expression is up-regulated 
upon stimulation of the T cell through the T-cell receptor. It 
then competes with CD-28 for binding to CD80 and CD86 on 
the APC. CTLA-4’s higher affinity for B7 ligands88 enables 
it to competitively inhibit CD28-mediated T-cell activation, 
thereby limiting the subsequent T-cell response (Fig. 1).90
This dual pathway is essential in the development of 
tolerance against antigens, including tumor antigens, after 
T-cell recognition. Therefore, blockade of the CTLA-4 
checkpoint pathway may be a reasonable approach to combat 
cancer, particularly in tumor types such as SCLC where 
evidence suggests that tumors may be avoiding or resisting 
natural immune responses.91,92 Use of monoclonal antibodies 
that block CTLA-4 are currently under investigation in 
multiple tumor types, including SCLC.93,94
Preclinical Evidence of Synergy between 
CTLA-4 Blockade and Chemotherapy
Preclinical data suggest that CTLA-4 blockade through 
anti-CTLA-4 antibodies enhances immune responses in some 
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cancer models. Cellular analysis has revealed that antibody-
mediated blockade of CTLA-4 on Teffs and Tregs contributes 
to antitumor activity in mouse models of cancer.95 CTLA-4 
blockade may prolong T-cell activation and thus intensify 
T-cell–mediated antitumor responses, potentially restricting 
tumor cell evasion of the immune system.96
As discussed previously, some preliminary evidence 
suggests that immunotherapy may work in concert with che-
motherapy and radiation, resulting in enhanced or synergis-
tic tumor control. Although the nuances of this phenomenon 
remain a subject of ongoing study, murine models have pro-
vided evidence of synergistic antitumor effects when CTLA-4 
blockade was used in combination with other modalities, par-
ticularly chemotherapy. In the M109 mouse model of lung 
cancer, treatment of animals with an anti-CTLA-4 monoclo-
nal antibody in combination with chemotherapeutic agents, 
such as gemcitabine, etoposide, and ixabepilone, revealed 
synergistic antitumor effects with particular regimens of 
agents.97–99 Furthermore, after combination treatment with 
CTLA-4 blockade and chemotherapy, animals rejected a sub-
sequent tumor rechallenge, suggesting the development of a 
protective immune response in this model.97,99
These preclinical data suggest that chemotherapy may 
improve the effect of CTLA-4 blockade. It is possible that this 
potential synergy may be the result of immunogenic tumor 
antigens, released through the cytotoxic effects of chemo-
therapy and then presented to T cells by APCs. In addition, 
certain chemotherapeutic drugs may distort tumor architec-
ture, enhancing the penetration of immunotherapeutic agents 
and the immune population.97,99 Furthermore, the described 
preclinical findings support the rationale for clinical investiga-
tion of CTLA-4-specific antibodies in regimens that include 
standard of care chemotherapy.
Clinical Application of CTLA-4 Blockade in SCLC
Blockade of the CTLA-4 receptor using ipilimumab,100 
a fully human anti-CTLA-4 monoclonal antibody, has 
been under clinical investigation in various tumor types.87 
Ipilimumab was recently approved at a dose of 3 mg/kg for 
treatment of unresectable or metastatic melanoma by regula-
tory authorities in more than 40 countries across the world, 
including the United States, Europe, and Australia,100–103 based 
on a pivotal phase III trial in metastatic melanoma that dem-
onstrated a statistically significant OS side-effect.104
Ipilimumab is presently under clinical investigation in 
other solid tumors, including SCLC (Table 1). A randomized, 
blinded phase II study examined two dosing schedules 
combining platinum-based chemotherapy (paclitaxel/
carboplatin) with ipilimumab 10 mg/kg in patients with 
ED-SCLC or stage IV NSCLC. This multicenter, international 
trial stratified 334 patients by disease type (ED-SCLC, n = 
130; NSCLC, n = 204 [data published elsewhere]).105,106 
Previously untreated patients with ED-SCLC in 32 centers 
across seven countries were randomized between June 2008 
and August 2009 to one of three treatment arms (1:1:1): 
ipilimumab given concurrently with paclitaxel/carboplatin 
(4 doses of ipilimumab + paclitaxel/carboplatin, followed 
by 2 doses of placebo + paclitaxel/carboplatin); ipilimumab 
in a phased schedule with paclitaxel/carboplatin (2 doses 
of placebo + paclitaxel/carboplatin, followed by 4 doses of 
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FIGURE 1.  Mechanism of action in T-cell activation: B7:CD28/CTLA-4 pathway. (Source: Shepherd et al.). Reprinted with  
permission from WoltersKluwer Health.89
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ipilimumab + paclitaxel/carboplatin); or a control regimen of 
placebo plus paclitaxel/carboplatin (up to 6 doses of placebo + 
paclitaxel/carboplatin). Induction treatment, as described 
above, was given every 3 weeks for up to six doses, and patients 
with no signs of disease progression were administered 
ipilimumab (phased-and concurrent-ipilimumab arms) or 
placebo (control arm) every 12 weeks as maintenance therapy 
(NCT00527735).106 The phased schedule of ipilimumab plus 
platinum-based chemotherapy, but not concurrent ipilimumab/
chemotherapy, resulted in improved outcomes compared with 
the placebo arm. irPFS in the phased schedule arm was 6.4 
months compared with 5.3 months in the placebo arm (HR = 
0.64; 95% CI, 0.40–1.02; p = 0.03). The best overall response 
rate (71% versus 53%, respectively) using irRC and OS (12.9 
versus 9.9 months, respectively; HR = 0.75; 95% CI, 0.46–
1.23; p = 0.13) also favored phased ipilimumab + paclitaxel/
carboplatin over paclitaxel/carboplatin alone, although the 
difference in survival did not reach statistical significance.106 It 
should be noted that the ED-SCLC cohort in this trial was not 
fully powered for a formal statistical comparison. Nevertheless, 
these data suggest that this chemoimmunotherapeutic regimen 
results in improved clinical benefit in patients with ED-SCLC, 
and that choice of schedule may affect the extent of benefit.
In general, ipilimumab did not exacerbate the adverse 
event profile of platinum-based chemotherapy in this study.106 
Patients treated with ipilimumab showed side effects consis-
tent with its immune-based mechanism of action, which were 
usually observed in other ipilimumab trials, such as fatigue 
and diarrhea.104,107 Adverse events that occurred more fre-
quently in the ipilimumab arms than the placebo arm included 
pruritus (19%–24% versus 5%, respectively), rash (24%–36% 
versus 2%, respectively), and diarrhea (26%–33% versus 16%, 
respectively).106 Overall, the incidence of treatment-related 
grade 3/4 adverse events appeared more often in the ipilim-
umab-containing arms, with 43% in the concurrent ipilim-
umab arm, 50% in the phased ipilimumab arm, and 30% in the 
placebo arm. Ipilimumab-related side effects were managed 
using protocol-specific guidelines. A randomized, multicenter 
phase III trial is currently underway to determine whether a 
phased schedule of ipilimumab plus a chemotherapy regi-
men of etoposide/platinum (carboplatin or cisplatin) versus 
etoposide/platinum alone extends OS in ED-SCLC patients. 
The study is estimated to enroll 912 patients on approximately 
227 sites among 34 countries. The primary outcome measure 
is OS with a time frame of approximately 40.8 months after 
the first subject is randomized, assessed until 816 events have 
been observed (NCT01450761). In addition, a second phase 
II trial is currently recruiting patients with ED-SCLC to deter-
mine whether the addition of ipilimumab to a chemotherapy 
regimen of etoposide/carboplatin extends PFS at 1 year in this 
patient population.108
PD-1 Receptor Blockade: Potential 
Clinical Applicability for SCLC
As mentioned above, PD-1 is another key immune-
checkpoint receptor expressed by activated T cells that medi-
ates immunosuppression. In vitro studies have shown that 
inhibiting the interaction between PD-1 and its ligand (PD-L1) 
can enhance T-cell responses, mediating preclinical antitumor 
activity.109,110 BMS-936558 (nivolumab, formerly MDX-1106) 
is a fully human anti-PD-1 monoclonal antibody that binds to 
PD-1. Data on the cohort of patients with NSCLC from the 
phase I dose-escalating study of nivolumab (compiled up to 
February 24, 2012) were recently reported111 and subsequently 
updated to reflect longer follow-up, with approximately 6 
additional months of patient accrual.
These data on a total of 127 patients with NSCLC were 
presented at the 2012 European Society of Medical Oncology 
(ESMO) Annual Meeting.112 Responses were evaluable in 
122 patients (48 squamous, 73 nonsquamous, and 1 unknown 
histology). Tumor responses were observed at all three doses 
assessed (1, 3, and 10 mg/kg twice a week) for squamous and 
nonsquamous histologies, with respective overall response rates 
of 6%, 27%, and 17%). Corresponding PFS rates at 24 weeks 
were 25%, 44%, and 31%. These encouraging data of nivolumab 
in NSCLC suggest the potential clinical applicability in SCLC. 
There are ongoing studies exploring the clinical activity of 
nivolumab in NSCLC, with phase III trials in both squamous 
and nonsquamous histology NSCLC (NCT01642004 and 
NCT01673867, respectively). These studies should help clarify 
the activity of nivolumab in NSCLC and potentially provide a 
path for future development in SCLC.
Challenges in Immunotherapy for SCLC
Researchers face many challenges in developing immu-
notherapeutic treatments for SCLC, including the high bur-
den of disease and lack of a specific target for vaccine-based 
TABLE 1.  Ipilimumab in SCLC—Summary of Phase II/III Clinical Trials 
Clinical Trial 
Identifier Phase Treatment Arm
Patient 
Population
Primary Outcome 
Measure Sponsor
NCT00527735 II Ipilimumab or placebo + paclitaxel/carboplatin 
(concurrent) vs. ipilimumab or placebo + paclitaxel/ 
carboplatin (sequential) vs. placebo/paclitaxel/carboplatin
Previously 
untreated SCLC 
(and NSCLC)
EORTC-QLQ-30 
questionnaire
Bristol–Myers Squibb
NCT01331525 II Ipilimumab/carboplatin/etoposide Extensive-stage 
SCLC
1-yr PFS Southampton University 
Hospitals NHS Trust
NCT01450761 III Ipilimumab/etoposide/platinum vs. etoposide/platinum Extensive-stage 
SCLC
OS Bristol–Myers Squibb
EORTC-QLQ, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; NHS, National Health Service; NSCLC, non–small cell lung cancer; 
OS, overall survival; PFS, progression-free survival; SCLC, small cell lung cancer.
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treatments. In addition, the complex genetic heterogeneity 
observed in SCLC patients may limit the success of any treat-
ment, including immunotherapy. Presently, there is not enough 
information to select SCLC patient subgroups that may 
best benefit from specific immunotherapeutic approaches. 
Prognostic and predictive biomarkers in SCLC have proven 
elusive, and identification of each may facilitate implementa-
tion of individualized treatment regimens that yield improved 
clinical benefit.
Moreover, data from the phase II study of ipilimumab 
and chemotherapy strongly imply that the timing and sched-
ule of immunotherapy in relation to other therapies may sig-
nificantly affect efficacy of the regimen in SCLC. The results 
presented by Reck et al.106 show that preceding ipilimumab 
therapy with lead-in doses of chemotherapy is preferable to 
concurrent treatment with ipilimumab and chemotherapy. It 
has been suggested that the more robust antitumor effect real-
ized from the phased administration of ipilimumab versus that 
of concurrent ipilimumab is because of the induction of tumor 
necrosis by chemotherapy. This induction results in changes 
in tumor architecture that releases tumor antigens into circu-
lation, enhancing expansion and infiltration of tumor-primed 
cytolytic T cells.97 Furthermore, phased administration facili-
tates chemotherapeutic reduction of high tumor burden, 
which is believed to diminish the effects of tumor-associated 
immunosuppression—ultimately increasing the effect of 
ipilimumab.76
It is important to consider that development of any 
immune response requires time. In advanced melanoma tri-
als with ipilimumab monotherapy, investigators reported 
some immediate responses of baseline lesions, but also noted 
some response patterns that differed from those of cytotoxic 
therapies, including an initial increase in total tumor burden 
and/or the development of new lesions before a response. 
These patterns may reflect the time required for an immune 
response to translate into clinical antitumor activity.113,114 To 
account for these response patterns that may be clinically ben-
eficial, but initially resemble disease progression, the ipilim-
umab melanoma trials stipulated that treatment should not be 
discontinued until progression is confirmed at a subsequent 
screening.104,107 For ED-SCLC, this plan of action must be bal-
anced by the significant clinical deterioration that may accom-
pany this aggressive disease. A further characterization of the 
risk-to-benefit profile of ipilimumab in ED-SCLC, and appro-
priate management of the patient’s treatment plan and adverse 
events will emerge from the ongoing phase III trial.
Despite the challenges associated with immunothera-
peutic intervention, treatment efficacy may be optimized by 
concomitant treatment with chemotherapy and radiation, and 
with chemotherapy alone, as previously noted. Preclinical 
studies suggest that chemotherapy and radiotherapy actively 
cause immunogenic tumor cell death and therefore may 
“prime” the immune system—the immunogenic properties 
of tumor cells may also be increased by enhancing major his-
tocompatibility complex class I expression.97,115,116 It also has 
been hypothesized that decreasing tumor mass through chemo-
therapy or radiation decreases the immunosuppressive proper-
ties of the tumor and creates an environment better suited for 
T-cell activation.76 Most recently, findings from a case report 
of a patient with melanoma suggest that the abscopal effect 
(a phenomenon in which local radiotherapy is associated with 
regression of metastatic cancer at a distance from the irradiated 
site) may be mediated by activation of the immune system—
providing a role for combination radioimmunotherapy.117 The 
authors noted temporal associations (i.e., tumor shrinkage with 
antibody responses to the cancer-testis antigen NY-ESO-1 and 
increases in antibody responses to other antigens) that fol-
lowed treatment with ipilimumab and radiotherapy. Although 
the biological effect behind this mechanism has not yet been 
characterized fully, it suggests that immunologic mechanisms 
play an instrumental role in the biological effect. Notably, in 
a murine breast-cancer model, decreased pulmonary metasta-
ses and improved survival were noted only for mice treated 
with radiotherapy in combination with CTLA-4 blockade—
supporting a role for combination radiotherapy and ipilim-
umab for the treatment of SCLC.118 Together, these findings 
support the clinical evaluation of different treatment schedules 
of immunotherapy with chemoradiotherapy or chemotherapy 
alone as strategies to circumvent the challenges associated 
with immunotherapeutic intervention for SCLC.
CONCLUSIONS AND FUTURE DIRECTIONS
The current treatment options for SCLC are limited 
and prognosis remains poor, underscoring the need for newer 
treatment strategies. Preclinical and early clinical studies 
have provided evidence of an immune response in SCLC, 
and the ongoing elucidation of the immunosuppressive tumor 
environment underlying the disease continues to support the 
development of not only novel agents, but also innovative 
approaches, such as immunotherapy. Targeting of immune 
inhibitory pathways with ipilimumab—and more recently, 
nivolumab—have emerged as promising anticancer strategies, 
partly because of their ability to target the immune system 
without reliance on the presence of specific tumor-associated 
antigens. Current standard treatment approaches are successful 
at inducing response, but the challenge lies in sustaining 
that initial benefit. The integration of immune modulators, 
such as ipilimumab, with traditional chemotherapeutic 
regimens—with and without radiotherapy—may lead to 
improved patient outcomes as a result of targeting multiple 
pathways with a combinatorial approach. These strategies 
may best be employed in maintenance regimens that aim to 
capitalize on the initial high sensitivity of SCLC to induction 
chemoradiotherapy.
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